Home » Clinical Trials » Leukemia » NCT06680752
NCT06680752

A Phase 1/2, Open-label, Multicenter Trial to Assess the Safety and Efficacy of ARD103 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Study Summary

This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.

Want to learn more about this trial?

Request More Info

Interventions

ARD103BIOLOGICAL
ARD103 autologous CAR-T cell therapy targeting CLL-1, single iv. infusion
CyclophosphamideDRUG
iv administration for lymphodepletion
FludarabineDRUG
iv administration for lymphodepletion

Study Locations

FacilityCityStateCountry
Novant Health Cancer InstituteCharlotteNorth CarolinaUnited States
Novant Health Cancer InstituteWinston-SalemNorth CarolinaUnited States
MD Anderson Cancer CenterHoustonTexasUnited States

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026